In 1996, the Accreditation Sub-Committee of the EBMT published a special report summarising current practice in Europe in relation to haemopoietic stem cell transplants for haematological diseases, solid tumours and immune disorders. An updated report is presented here. The major change has been the recognition that transplant practice is appreciably different between children and adults, who should therefore be considered in separate categories. The autoimmune disorders for which autografting may be useful are now specified. Non-CML myeloproliferative disorders and AL amyloidosis have been added to the list of indications for transplant procedures in adults. Other changes have been incorporated into the revised tables.
report may be regarded as controversial. It was not our intention in this report to review the literature in detail nor to provide reasoned arguments for and against the decision to offer a given patient a transplant in a given clinical situation. Rather we have attempted to summarise the opinions and practice of clinicians working in transplant centres in Europe in 1998.
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Patient age
The age of an individual patient remains one of the most important determinants of outcome following both allogeneic and autologous HSCT procedures. As a broad generalisation it seems reasonable to recommend limits of 65 years for autograft procedures, of 60 years for allograft procedures using HLA-identical sibling donors and of 45 years for unrelated donor transplants. There will always be cases where it is reasonable to exceed these arbitrary limits. (For the purposes of this document, patients up to the age of 16 years are classified as children.)
Categorisation of transplant procedures
The categories into which different transplant procedures were allocated were defined in the 1996 publication and have given rise to some discussion subsequently. These categories are recapitulated with some modifications below:
1. Routine (R): Transplants categorised as routine are carried out in many centres in Europe, often without entering the patient into an institutional or national study. The results of such transplants are in general reasonably well defined and compare favourably (or are superior to) results of non-transplant treatment approaches. The term 'standard' has been proposed in place of 'routine' but 'routine' has been retained. Obviously defining a transplant as 'routine' does not mean that it is necessarily the optimal therapy for a given patient in all clinical circumstances. 'Routine' transplants may be performed in any specialist centre with experience with HSCT procedures provided they have an appropriate infrastructure as defined by EBMT guidelines.
Clinical Research Protocol (CRP):
The value of transplants for patients in these categories is not yet clearly established. Candidate patients are therefore offered the opportunity of undergoing allo-or auto-SCT in the context of a clinical research protocol that has been designed specifically to cover a series of patients who satisfy defined diagnostic criteria. The protocol may have been written for a single institution or may reflect national or international multi-centre collaboration. The protocol will usually have been approved by a Research Ethics Committee or an Institutional Review Board. It is implied that the results of the study are intended for presentation to and/or publication for the medical community at large. It should be stressed that the CRP may or may not be a randomised comparison of two or more approaches to treatment.
Developmental (D):
Transplants have been classified as developmental if there is little or no national or international experience with this particular type of transplant. In general such transplants will involve single cases or small pilot series undertaken by transplant units with acknowledged special expertise in the management of that particular disease. The category also covers fundamentally new approaches to the management of a disease which in a different status or phase may already be classified under (R) or (CRP) above. Protocols for 'D' transplants will usually have been approved by local Research Ethics Committees. Again, it is implied that the results of 'D' transplants are intended for presentation or publication.
Not generally recommended (NR):
This category covers procedures contemplated for a disease in a phase or status in which patients are not conventionally treated by haemopoietic SCT. Clearly there will be some overlap between 'NR' and 'D'. It also includes early disease stages when results of conventional treatment do not justify the additional risk of transplant-related mortality, or when the disease is so advanced that the chance of success is so small that the risk of the harvest procedure for the normal donor is difficult to justify. 'NR' may not apply to specific situations where there exists a syngeneic donor.
Status of transplants in specific diseases in adults
The updated classification of SCT procedures in adults is shown in Table 1 . The principal changes include a revised classification of the lymphomas and the myelodysplastic syndromes. The autoimmune disorders that may be considered for autografting are specified separately. The use of autografting for AL amyloidosis is being studied in specialist centres and is therefore included in Table 1 . An abbreviated version of the text published in 1996 1 with appropriate modifications appears below:
Acute myeloid leukaemia (AML)
Patients with AML in first remission may be treated by allo-or auto-SCT on an individual basis or within the context of a clinical study. Patients who fail to achieve complete remission after two courses of induction chemotherapy may be treated by allo-BMT with an HLA-identical sibling, or if time permits, by allo-BMT from a matched unrelated donor. Patients with AML in early relapse or in second or later remission may also be treated by allo-SCT. Patients in established relapse are not generally recommended for allo-SCT. Transplants involving unrelated donors for AML in remission should proceed largely in the context of a clinical research protocol.
Patients with AML in first remission, early relapse or later remission may be treated by auto-SCT with or without purging of harvested marrow.
The results of transplant procedures for AML must always be compared with results of contemporary chemotherapy regimens; some groups discourage allograft procedures for patients in first remission with cytogenetically 'favourable' sub-types of AML.
Acute lymphoblastic leukaemia (ALL)
Selected patients with ALL, especially those with poor prognostic features (eg adults, patients of any age with Philadelphia chromosome-positive ALL), are currently considered for treatment by allogeneic BMT in first remission if they have a sibling donor; autografting may be a reasonable alternative. Both procedures can be performed on an ad personam basis or in the context of a clinical research protocol. The same stipulations apply to a patient with standard risk ALL treated with chemotherapy only in first remission who relapses and then is restored to second remission with further chemotherapy. As with AML, ALL patients who fail to achieve complete remission after two courses of induction chemotherapy may be treated by allo-BMT with an HLA-identical sibling, or if time permits, by allo-BMT from a matched unrelated donor.
Chronic myeloid leukaemia (CML)
Patients with CML under the age of 60 may be treated by allogeneic BMT with marrow from sibling donors on a routine basis. The transplant should ideally be performed in chronic phase within 1 year from diagnosis but patients in advanced phases may also be offered transplants on an individual basis. The timing of transplant for patients with compatible donors who achieve a major or complete cytogenetic response to interferon-␣ remains uncertain. Transplants using unrelated donors are usually undertaken in the context of clinical research protocols. Autografts for patients in chronic phase up to age 65 years may be performed for selected patients within approved clinical research protocols; autografts for patients with advanced disease may be performed in selected cases within the clinical trial setting.
Myeloproliferative disorders other than CML
There is little experience with the use of either allo-or auto-SCT in the management of patients with primary polycythaemia, essential thrombocythaemia or primary myelofibrosis. It would seem reasonable however that any patient in this category with 'high-risk' disease who has an HLAidentical sibling could be considered for allografting in a Ͻ65 --CRP R = in routine use for selected patients; CRP = to be undertaken in approved Clinical Research Protocols; D = developmental or pilot studies can be approved in specialist units; NR = not generally recommended; NA = not applicable; VUD = volunteer unrelated donor; MRD = minimal residual disease; CR1, 2, 3 = first, second, third complete remission; RA = refractory anaemia; RARS = refractory anaemia with ring sideroblasts; RAEB = refractory anaemia with excess blasts; CMMoL = chronic myelomonocytic leukaemia; sAML = secondary acute myeloid leukaemia. This classification does not cover patients for whom a syngeneic donor is available.
CRP. Allo-SCT using alternative donors or auto-SCT for patients in this category should be regarded as 'developmental'.
Chronic lymphocytic leukaemia (CLL)
Selected patients under the age of 55 years with HLA-identical sibling donors may be treated by allogeneic transplantation in the context of a clinical research protocol. Such patients will usually be adults with poor prognostic features at diagnosis who have responded to conventional therapy pre-transplant. Autologous haematopoietic stem cell transplantation represents a new therapeutic approach for CLL and should currently be performed in the context of a clinical research protocol. It should be an option for patients under 65 years who have achieved complete remission or very good partial remission after conventional therapy.
Non-Hodgkin's lymphoma
Auto-SCT is currently offered as therapy to patients with sensitive relapse of high-or intermediate-grade NHL or to some adult patients with high-or intermediate-grade NHL who have two or more poor prognostic features according to the Shipp index, for whom high-dose chemotherapy is increasingly being used to consolidate first response to conventional chemotherapy. Lymphoblastic lymphoma may be consolidated in remission by auto-SCT. Allo-SCT for lymphoblastic lymphoma might be considered for young adults in first remission. Auto-SCT for low-grade lymphoma is currently being studied in the context of clinical research protocols. Since patients with mantle cell lymphoma do particularly badly with chemotherapy alone, they should be offered treatment by auto-SCT as soon as possible.
Hodgkin's disease
Auto-SCT is currently offered as therapy to patients with HD treated initially by chemotherapy who relapse and to patients with advanced HD treated by chemotherapy, sometimes by radiotherapy, who do not enter complete remission. In general allo-SCT does not produce a better result than auto-SCT but allo-SCT may be considered for patients with an HLA-identical sibling donor who relapse post auto-SCT.
Myeloma
Allogeneic BMT in multiple myeloma is preferably carried out in patients up to the age of 55 years who have responded to first-line treatment, or before second-line treatment if the patient has not responded to first-line treatment. Allogeneic transplantation with sibling donors may be considered for selected patients who are non-responsive or who have already received several lines of treatment. Transplant with unrelated donors should only be considered on a 'developmental' basis. Autologous transplantation is an option for patients below 65 years of age who respond to first-line treatment.
Myelodysplastic syndromes (MDS)
Allogeneic BMT is considered the treatment of choice for patients with MDS or secondary AML (sAML) offering a good chance of long-term disease-free survival if the transplant is performed in an early stage of the disease (ie refractory anaemia or refractory anaemia with excess of blasts) or if the patient is transplanted in complete remission after chemotherapy. The transplant is limited to patients aged less than 55 years with an HLA-identical sibling. Allogeneic BMT may also be considered for patients aged less than 45 years who have a fully matched unrelated donor. All patients, including those without excess of blasts, should be conditioned with 'marrow ablative' therapy rather than with an 'immunosuppressive' regimen, such as cyclophosphamide alone. Autologous transplants are currently under consideration for MDS patients who achieve complete remission after treatment with chemotherapy.
Severe aplasia
Allogeneic bone marrow transplantation from an HLAidentical sibling is the treatment of choice for patients with acquired severe aplastic anaemia (SAA) under the age of 45 years. The conditioning probably should not include radiation because of the high risk of secondary tumours. In older patients, or in the absence of a matched sibling, an initial course of immunosuppressive treatment is recommended. Growth factors should not be used as single agents, but rather in association with immunosuppression, in the context of clinical trials. Unrelated donor transplants are still associated with significant morbidity and should be undertaken within clinical research protocols.
Solid tumours
Despite much research in this field, no single solid tumour can be regarded as a standard indication for blood or marrow stem cell autografting. Most autografts should be undertaken as part of approved clinical studies and most such protocols should now be randomised. For selected solid tumours allogeneic transplants from HLA-identical sibling donors may be undertaken at specialist institutions on a developmental basis.
Autoimmune disorders
Allo-or auto-SCT following appropriate conditioning is being considered on a developmental basis for selected patients with severe intractable autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, refractory (splenectomised) ITP and others. Dependency of high steroid doses above the 'Cushing threshold' and causing skeletal damage could be an indication. In auto-SCT the use of T cell depletion (and possibly B cell depletion) should be considered.
AL amyloidosis
A number of patients with AL amyloidosis have been treated by auto-SCT, both in North America and in Europe. Some patients have obtained clear-cut clinical benefit. Such studies should presumably continue in the context of a clinical research protocol. Allo-SCT should be discussed for individual patients on a developmental (D) basis. (Table 2) 
Status of transplants in specific diseases in children
Acute myeloid leukaemia (AML)
The results of transplant procedures for AML must always be compared with results of contemporary chemotherapy regimens, which, in general, are better in children than in adults. This is why some groups, such as the I-BFMSG, only recommend haemopoietic SCT in first remission for children with 'unfavourable' FAB types. The question whether allogeneic HSCT leads to better results than autologous transplantation is also unanswered. In second remission results of chemotherapy are poor. That is why all types of SCT are recommended.
Acute lymphoblastic leukaemia (ALL)
Selected patients with poor prognostic factors are currently considered for allo-SCT in first remission if they have a sibling donor, or in some centres with an unrelated matched donor. Auto-SCT, however, cannot be recommended. The situation with allo-SCT in CR2 is somewhat complicated. Children who relapse very early (during the first year of treatment) or who suffer from a T-ALL have no chance of cure with conventional chemotherapy. Thus allo-SCT from a sibling or an unrelated donor is recommended. For all later relapses occurring up to 4 years after the first diagnosis allo-SCT using a sibling donor can be recommended. At a later stage of the disease, auto-SCT in CR2 is only recommended within a clinical research protocol.
Chronic myeloid leukaemia (CML)
The recommendations for children with CML are identical to those for adults. Due to the lower complication rate in children the use of unrelated donors may be considered more readily.
Malignant lymphoma
The prognosis of Hodgkin's disease in children is extremely good and relapses are rare. In such cases auto-SCT can be recommended. Bone marrow transplantation in NHL should be done usually as in ALL.
Myelodysplastic syndrome (MDS)
Allo-SCT from a sibling donor is the treatment of choice for children with standard myelodysplastic syndromes, chronic myelomonocytic leukaemia as well as secondary AML. Since the chance of a cure is extremely poor with conventional chemotherapy allogeneic HSCT from an unrelated donor can also be recommended within approved clinical research protocols. The role of auto-SCT in children with MDS remains controversial. A limited number of children with advanced stage MDS has been treated by autografting. If no sibling donor is available, then auto-SCT may be considered, especially in children who are expected to enter complete remission with relative ease, eg with a short history, normal or 'favourable' cytogenetics.
Immunodeficiency syndromes/inborn errors
For severe immunodeficiency syndromes such as severe combined immunodeficiency (SCID), allo-SCT from a matched donor or a haploidentical SCT from a parent is recommended.
Aplastic anaemia, pure red cell aplasia (BlackfanDiamond) and Fanconi anaemia
For children with acquired severe aplastic anaemia and an HLA-identical family donor, allo-SCT is the treatment of choice. For patients who lack a compatible family member donor, a course of intensive immunosuppressive therapy (IS) (antilymphocyte globulin and cyclosporin A), possibly with addition of a haemopoietic growth factor (G-CSF), is indicated. For children who fail their first course of IS, the search should be initiated for an unrelated donor (UD) while they receive a second course of IS. If a 'matched' unrelated donor is identified, the patients should be treated in the context of a clinical research protocol.
Children with Blackfan-Diamond anaemia who have a matched sibling should be transplanted if they do not respond to steroids and also if they do not eventually become independent of these drugs, since long-term administration is associated with the risk of severe side-effects in children.
Children with Fanconi anaemia (FA) should be transplanted if they have a normal HLA-identical sibling donor. For FA patients who lack genetically HLA-identical donors, a transplant should be considered with a 'matched' unrelated donor or with cord blood stem cells in the context of a CRP.
Haemoglobinopathies
For young patients with homozygous thalassaemia who have an unaffected HLA-identical sibling, allo-HSCT is 6 probably the treatment of choice. Allo-SCT using an HLAidentical sibling donor should also be considered for young patients with homozygous SS disease who have one of the major complications listed in the 1996 Special Report. 1 Such complications include recurrent pain episodes, pulmonary manifestations, osteopetrosis, transient neurological deficits or problems concerning future medical care such as limited availability of medical care or blood products.
Solid tumours
Despite much research in this field no single solid tumour can be regarded as a standard indication for blood or marrow stem cell autografting in children. The only exception might be neuroblastoma (stage 4 beyond the age of 1 year, or high-risk factors in lower stages), but autografting should be performed in accordance with approved protocols. An improvement of survival and even disease-free survival can be expected. Autografts in solid tumours should always be undertaken as part of approved clinical studies.
Children with solid tumours may benefit from autologous grafting following high-dose chemotherapy in the following situations:
• Germ cell tumours: after a relapse or with progressive disease • Ewing's sarcoma: stage IV and after a localised relapse • Soft tissue sarcoma: stage IV or after a non-resectable relapse • Neuroblastoma: stage 4 in a child older than 1 year lower stages with chromosome 1p deletion and/or nmyc amplification • Wilms tumour: high-risk histology or relapse • Osteogenic sarcoma: as yet the value of SCT is not clear • Brain tumours: children with medulloblastoma and highgrade gliomas responsive to chemotherapy
In general allo-SCT cannot be recommended in children with solid tumours. Allo-SCT may however be undertaken on a developmental basis in specialist centres.
Autoimmune diseases
Allo-or auto-SCT is being considered on a developmental basis for selected patients with severe intractable autoimmune diseases such as multiple sclerosis (extremely rare in children), systemic sclerosis or selected cases of rheumatoid arthritis. Dependency on high steroid doses above the 'Cushing threshold' could be an indication. In auto-SCTs for autoimmune diseases the use of T cell depletion (and possibly B cell depletion) must be considered.
Haploidentical stem cell transplants
In severe immunodeficiency, haploidentical haemopoietic SCT is the treatment of choice if no matched sibling is available. At present better methods for T cell depletion with a yield of high doses of CD34 + stem cells are being developed. This means that haemopoietic SCT can be used in specialised units in some other diseases where the use of an unrelated donor would be recommended (such as very early relapse of ALL, osteopetrosis or resistant severe aplastic anaemia).
